Protective Effects of Valproic Acid in Preventing of Myelin Tissue Destruction and Maintaining Its Density in the Corpus Callosum of Mouse Brain

Document Type : Original Article(s)

Authors

1 PhD Student, Department of Anatomical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Anatomical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Anatomical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Environmental toxic factors, with their destructive effects on nerve cells and myelin tissue, can induce nervous system dysfunction. The neuroprotective role of valproic acid as an inhibitor of Glycogen synthase kinase 3β (GSK3-β) has been proven in some neurodegenerative diseases. In the present study, the effects of this combination were investigated in preventing myelin tissue destruction and maintaining its density in the corpus callosum of mouse brain.
Methods: 40 female C57BL/6 mice weighing 20-25 grams were divided into four groups including control, sham, cuprizone and, valproic acid/cuprizone groups. The valproic acid combination was used intraperitoneally, daily, and at a dose of 300 mg/kg. At the end of the research, to check myelin density, Teloidin blue staining, immunohistochemistry and, real-time methods were used.
Findings: The results showed that the density of myelin and the percentage of cells expressing the Myelin Basic Protein (MBP) marker increased significantly in the group that received valproic acid compared to the cuprizone group. In addition, the results of myelin-specific gene expression analysis showed that the use of valproic acid can increase the expression of this gene.
Conclusion: The results of the present study showed that valproic acid has the ability to prevent myelin tissue destruction and maintain its density, and therefore, the use of this combination can be a suitable combination to prevent and reduce the progression of diseases that destroy nerve tissue.

Highlights

Sahar Ghosouri: PubMed

Mitra Soleimani: PubMed ,Google Scholar

Nazem Ghasemi: PubMed ,Google Scholar

Keywords

Main Subjects

References

  1. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J 2017; 19(1): 1-10.
  2. Lotfi A, Soleimani M, Ghasemi N. Astaxanthin reduces demyelination and oligodendrocytes death in a rat model of multiple sclerosis. Cell J 2021; 22(4): 565-71.
  3. Bagheri E, Marandi SM, Ghasemi N. Evaluation of curcumin effects on improvement of muscle strength, prevention of oligodendrocytes and myelin damage in brain, in an animal model of multiple sclersosis (MS) [in Persian]. J Kurdistan Univ Med Sci 2018; 23(5): 55-64.
  4. Mohammadi-Rad M, Ghasemi N, Aliomrani M. Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis. Res Pharm Sci 2019; 14(5): 424-31.
  5. Ghosouri S, Soleimani M, Bakhtiari M, Ghasemi N. Evaluation of in vivo lithium chloride effects as a GSK3-β inhibitor on human adipose derived stem cells differentiation into oligodendrocytes and re-myelination in an animal model of multiple sclerosis. Mol Biol Rep 2023; 50(2): 1617-25.
  6. Moradi V, Esfandiary E, Ghanadian M, Ghasemi N, Rashidi B. The effect of Zingiber officinale extract on preventing demyelination of corpus callosum in a rat model of multiple sclerosis. Iran Biomed J 2022; 26(4): 330-9.
  7. Bakhtiari M, Ghasemi N, Salehi H, Amirpour N, Kazemi M, Mardani M. Evaluation of Edaravone effects on the differentiation of human adipose derived stem cells into oligodendrocyte cells in multiple sclerosis disease in rats. Life Sci 2021; 282: 119812.
  8. Chung W-S, Lin C-L, Kao C-H. Carbon monoxide
    poisoning and risk of deep vein thrombosis and pulmonary embolism: a nationwide retrospective cohort study. J Epidemiol Community Health 2015; 69(6): 557-62.
  9. Mardani M, Ganji R, Ghasemi N, Kazemi M, Razavi S. Impact of intraventricular human adipose-derived stem cells transplantation with pregnenolone treatment on remyelination of corpus callosum in a rat model of multiple sclerosis. Cell J 2022; 24(12): 748-56.
  10. Razavi S, Nazem G, Mardani M, Esfandiari E, Salehi H, Esfahani SHZ. Neurotrophic factors and their effects in the treatment of multiple sclerosis. Adv Biomed Res 2015; 4: 53.
  11. Shnayder NA, Grechkina VV, Khasanova AK, Bochanova EN, Dontceva EA, Petrova MM, et al. Therapeutic and toxic effects of valproic acid metabolites. Metabolites 2023; 13(1): 134.
  12. Silva MR, Correia AO, Dos Santos GCA, Parente LLT, de Siqueira KP, Lima DGS, et al. Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. Pharmacol Biochem Behav 2018; 167: 17-28.
  13. Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol 2019; 17(10): 926-46.
  14. Duan Q, Li S, Wen X, Sunnassee G, Chen J, Tan S, et al. Valproic acid enhances reprogramming efficiency and neuronal differentiation on small molecules staged-induction neural stem cells: suggested role of mTOR signaling. ront Neurosci 2019; 13: 867.
  15. Azuchi Y, Kimura A, Guo X, Akiyama G, Noro T,
    Harada C, et al. Valproic acid and ASK1 deficiency ameliorate optic neuritis and neurodegeneration in an animal model of multiple sclerosis. Neurosci Let 2017; 639: 82-7.
  16. Amirzargar MA, Yaghubi F, Hosseinipanah M, Jafari M, Pourjafar M, Rezaeepoor M, et all. Anti-inflammatory effects of valproic acid in a rat model of renal ischemia/reperfusion injury: alteration in cytokine profile. Inflammation 2017; 40(4): 1310-18.
  17. Celik E, Tunali S, Gezginci-Oktayoglu S, Bolkent S, Can A, Yanardag R. Vitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis. Toxicol Mech Methods 2021; 31(8): 600-8.
  18. Nielsen NM, Svanström H, Stenager E, Magyari M, Koch‐Henriksen N, Pasternak B, et al. The use of valproic acid and multiple sclerosis. Pharmacoepidemiol Drug Saf 2015; 24(3): 262-8.
  19. Ghasemi‐Kasman M, Zare L, Baharvand H, Javan M. In vivo conversion of astrocytes to myelinating cells by miR‐302/367 and valproate to enhance myelin repair. J Tissue Eng Regen Med 2018; 12(1): e462-e472.
  20. Satoh A, Fujimoto S, Irie T, Suzuki T, Miyazaki Y, Tanaka K, et al. Valproic acid promotes differentiation of adipose tissue-derived stem cells to neuronal cells selectively expressing functional N-type voltage-gated Ca2+ channels. Biochem Biophys Res Commun 2022; 589: 55-62.
  21. Vecera CM, Jones G, Chong AC, Ruiz AC, Rong C, Soares JC, et al. Intracellular signaling cascades in bipolar disorder. Biomarkers in Bipolar Disorders: Elsevier; 2022. p. 331-47.
  22. Zhu X, Yao Y, Hu Y, Yang J, Zhang C, He Y, et al. Valproic acid suppresses cuprizone-induced hippocampal demyelination and anxiety-like behavior by promoting cholesterol biosynthesis. Neurobiol Dis 2021; 158: 105489.
  23. Pazhoohan S, Satarian L, Asghari AA, Salimi M, Kiani S, Mani AR, et al. Valproic Acid attenuates disease symptoms and increases endogenous myelin repair by recruiting neural stem cells and oligodendrocyte progenitors in experimental autoimmune encephalomyelitis. Neurodegener Dis 2014; 13(1): 45-52.
  24. Jang S, Jeong HS. Histone deacetylase inhibition-mediated neuronal differentiation via the Wnt signaling pathway in human adipose tissue-derived mesenchymal stem cells. Neurosci Lett 2018; 668: 24-30.
Journal of Isfahan Medical School
Volume 41, Issue 739
3rd Week, December
November and December 2023
Pages 905-911

Files

History

  • Receive Date: 04 October 2023
  • Accept Date: 09 December 2023

Share

How to cite

Statistics